Therapeutically, this suggests the potential cross-applicability of cGAS inhibitors, which could dampen hyperactive immune responses in IBD or modify the tumor microenvironment in GI cancers, presenting a dual benefit. The gene discussed is CGAS; the disease is inflammatory bowel disease.